Short-term hemodynamic effect of a new oral PGI2 analogue, Beraprost, in primary and secondary pulmonary hypertension

American Journal of Cardiology

Volumn 78, Issue 2, 1996, Pages 244-247

  Saji, Tsutomu ^a   Ozawa, Yasufumi ^a   Ishikita, Takashi ^a   Matsuura, Hiroyuki ^a   Matsuo, Norio ^a  

^a TOHO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BERAPROST; PROSTACYCLIN DERIVATIVE;

ADULT; AORTA PRESSURE; ARTERIAL OXYGEN SATURATION; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART CATHETERIZATION; HEART INDEX; HEART RIGHT ATRIUM PRESSURE; HEMODYNAMICS; HUMAN; LUNG ARTERY PRESSURE; LUNG CAPILLARY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SYSTEMIC VASCULAR RESISTANCE;

EID: 0030055358     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00269-X     Document Type: Article

References (13)

1. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327:70-75.
2. Watkins WD, Crone RK, Shannon DC, Levine L. Prostacyclin and prostaglandin E1 for severe idiopathic pulmonary hypertension. Lancet 1980;1: 1083.
3. Nishio S, Matsuura H, Kawai N, Fukatsu Y, Hirano T, Nishikawa N, Kaneoka K, Umetsu T. The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species. Jpn J Pharmacol 1988;47:1-10.
4. Higgenbottam T. The place of prostacyclin in the clinical management of primary pulmonary hypertension. Am Rev Respir Dis 1987;136:782-786.
5. Rubin JJ, Mendoza J, Hood M, McGoon M, Barst R, William BW, Diehl JH, Crw J, Long W. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (Epoprosterol). Ann Intern Med 1990;112:485-491.
6. Cremona G, Higenbottam T. Role of prostacyclin in the treatment of primary pulmonary hypertension. Am J Cardiol 1995;75:67A-71A.
7. Barst RJ, Rubin JL, McGoon MD, Caldwell EJ, Long WA, Levy PS. Long-term continuous prostacyclin treatment improves survival in primary pulmonary hypertension. J Am Coll Cardiol 1993;21: 368A.
8. Rich S. Medical treatment of primary pulmonary hypertension: a bridge to transplantation? Am J Cardiol 1995;75:63A-66A.
9. Jones DK, Higenbottom TW, Wallwork J. Treatment of primary pulmonary hypertension with intravenous epoprosterol (Prostacyclin). Br Heart J 1987;57:270-278.
10. Murata T, Murai T, Kanai T, Ogaki Y, Sanai K, Kanda H, Sato S, Kajikawa N, Umetsu T, Matsuura H, Fukatsu Y, Isogaya M, Yamada N, Nishio S. General pharmacology of Beraprost sodium, second communication: effect on the autonomic, cardiovascular and gastrointestinal systems, and other effects. Arzneim-Forsch. Drug Res 1989;39:867-876.
11. 2 analogue. Br J Pharmacology 1986;89:703-711.
12. Nishio S, Yamada N, Endoh T, Isogaya M, Fukatsu Y, Nishimura S, Kanai N, Umetsu T. Effect of Beraprost sodium on peripheral circulatory disturbances induced by various stimuli. Drug Res 1989;39:1229-1234.
13. Kriner G, Siostrzonek P, Heinz G, Pabinger I, Roden M, Gossinger H. Drug-testing in patients with pulmonary hypertension of unknown cause. Eur Heart J 1992;13:776-780.